Acumen Pharmaceuticals Inc

NASDAQ ABOS

Download Data

Acumen Pharmaceuticals Inc Return on Tangible Equity (ROTE) 3 year CAGR for the year ending September 20, 2024

Acumen Pharmaceuticals Inc Return on Tangible Equity (ROTE) 3 year CAGR is NA for the year ending September 20, 2024. Return on tangible equity measures the profitability of a company relative to its tangible equity, which is shareholders' equity minus goodwill and intangible assets. It is calculated by dividing the net income by the tangible equity. This ratio indicates the return generated for each unit of tangible equity invested by the shareholders. A higher return on tangible equity suggests better profitability and value creation for the shareholders' tangible investment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email